The Golgin A5 (GOLGA5) antibody is a tool used to detect GOLGA5. a member of the golgin family of proteins localized to the Golgi apparatus. GOLGA5. also known as RET ligand 4 (RETL4), is characterized by its coiled-coil domains and plays a role in maintaining Golgi structure, vesicle trafficking, and protein sorting. It interacts with other golgins and Rab GTPases to mediate tethering and fusion events critical for Golgi organization.
GOLGA5 antibodies are widely utilized in research to study Golgi dynamics, cellular stress responses, and cancer biology. Notably, GOLGA5 gained attention due to its involvement in chromosomal rearrangements, particularly the RET-GOLGA5 fusion in thyroid and other cancers, which drives oncogenic signaling. Antibodies targeting GOLGA5 help identify such fusion proteins and assess Golgi integrity in disease models.
In autoimmune contexts, anti-GOLGA5 autoantibodies have been reported in subsets of patients with Sjögren’s syndrome or systemic lupus erythematosus, though their clinical significance remains under investigation. Commercial GOLGA5 antibodies are validated for techniques like Western blotting, immunofluorescence, and immunohistochemistry, often serving as Golgi markers. Researchers must consider potential cross-reactivity with homologous golgins and validate specificity using knockout controls. Ongoing studies explore its roles in neurodegeneration, viral infection, and Golgi-targeted therapies.